Taiwanese drug developer Senhwa Biosciences said Sunday that its investigational drug for the treatment of severe COVID-19 infections has received positive reviews from an independent monitoring group in the United States, and its clinical trials can go forward.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
TSMC investment drives Kaohsiung's urban development: Mayor
12/26/2024 09:12 PM - Cross-Strait
NIA stops 124 Chinese nationals from visiting Taiwan using forged documents
12/26/2024 08:53 PM - Politics
Presidential Office simulation shows need for better government coordination
12/26/2024 08:40 PM - Politics
Ko Wen-je's 10-year rise and fall in Taiwanese politics
12/26/2024 08:13 PM - Politics
Cabinet 'likely' to ask for Legislature revote on revenue allocation bill
12/26/2024 08:03 PM